Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases

Inclusion Criteria: * Diagnosis of malignant neoplasm, tuberculosis, or hepatitis C (confirmed by clinical, laboratory, and/or histopathological criteria) * Age between 18 and 50 years at the time of enrollment * Receiving standard basic therapy (chemotherapy, anti-tuberculosis therapy, or antiviral therapy) according to national clinical protocols * Signed informed consent to participate in the study * Willingness to comply with study procedures and follow-up visits * ECOG performance status ≤ 2 or equivalent Exclusion Criteria: * Severe concomitant diseases (e.g., decompensated cardiovascular, renal, or hepatic failure) that could interfere with study participation or outcome assessment * Known hypersensitivity or contraindications to Naderin (sodium nucleinate) or its components * Pregnancy or lactation * Participation in any other interventional clinical trial within 30 days prior to enrollment * Active or uncontrolled infections (other than the primary study condition) * Severe immunodeficiency (e.g., HIV/AIDS, advanced hematological malignancies) not related to the primary study condition * Mental or cognitive impairment that would preclude informed consent or compliance with study procedures * History of organ transplantation requiring immunosuppressive therapy * Any other condition that, in the investigator's opinion, would make the participant unsuitable for the study